Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 26  •  04:00PM ET
6.77
Dollar change
-0.06
Percentage change
-0.88
%
Index
-
P/E
-
EPS (ttm)
-1.25
Insider Own
2.58%
Shs Outstand
36.34M
Perf Week
-1.74%
Market Cap
246.02M
Forward P/E
-
EPS next Y
-0.75
Insider Trans
0.00%
Shs Float
35.40M
Perf Month
-3.15%
Enterprise Value
203.18M
PEG
-
EPS next Q
-0.24
Inst Own
45.59%
Perf Quarter
-5.31%
Income
-38.90M
P/S
13.08
EPS this Y
40.14%
Inst Trans
0.43%
Perf Half Y
15.23%
Sales
18.81M
P/B
4.14
EPS next Y
10.90%
ROA
-57.92%
Perf YTD
-13.98%
Book/sh
1.64
P/C
4.89
EPS next 5Y
-
ROE
-70.59%
52W High
8.95 -24.36%
Perf Year
31.97%
Cash/sh
1.38
P/FCF
-
EPS past 3/5Y
-0.76% -2.41%
ROIC
-62.42%
52W Low
3.76 80.05%
Perf 3Y
-41.28%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
34.06% 17.12%
Gross Margin
71.07%
Volatility
4.61% 5.76%
Perf 5Y
-63.35%
Dividend TTM
-
EV/Sales
10.80
EPS Y/Y TTM
-2.80%
Oper. Margin
-202.56%
ATR (14)
0.39
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
5.71
Sales Y/Y TTM
58.59%
Profit Margin
-206.76%
RSI (14)
48.33
Dividend Gr. 3/5Y
- -
Current Ratio
6.56
EPS Q/Q
45.57%
SMA20
-2.44%
Beta
0.72
Payout
-
Debt/Eq
0.13
Sales Q/Q
103.62%
SMA50
3.93%
Rel Volume
0.73
Prev Close
6.83
Employees
162
LT Debt/Eq
0.05
SMA200
7.39%
Avg Volume
185.16K
Price
6.77
IPO
Jun 09, 2016
Option/Short
Yes / Yes
Trades
Volume
134,985
Change
-0.88%
Date Action Analyst Rating Change Price Target Change
Jul-23-24Initiated Lake Street Buy $16.50
Jul-16-24Upgrade Stifel Hold → Buy $9 → $12
Nov-28-23Initiated Stifel Hold $11
Aug-04-23Downgrade Raymond James Strong Buy → Outperform $20 → $200
Mar-21-23Downgrade Jefferies Buy → Hold $5.50 → $10
Sep-15-20Initiated Jefferies Buy
May-20-26 04:49PM
May-14-26 07:00AM
May-13-26 08:41PM
May-07-26 04:05PM
May-06-26 09:33AM
10:30AM Loading…
Apr-29-26 10:30AM
Apr-16-26 08:37AM
Apr-14-26 07:30AM
Apr-01-26 08:15AM
Mar-27-26 07:45AM
Mar-13-26 10:30AM
Mar-09-26 08:30AM
Mar-06-26 12:02AM
Mar-05-26 11:06PM
05:20PM
04:05PM Loading…
04:05PM
Mar-04-26 07:22AM
Mar-02-26 10:00AM
08:06AM
Feb-26-26 10:00AM
08:15AM
Feb-25-26 12:15PM
Feb-12-26 04:30PM
08:30AM
Feb-05-26 08:00AM
Jan-27-26 04:30PM
Jan-16-26 08:55AM
Jan-15-26 09:26AM
07:30AM
Jan-12-26 08:00AM
07:45AM Loading…
Jan-06-26 07:45AM
Dec-30-25 04:30PM
Dec-24-25 01:15PM
Dec-23-25 08:00AM
Dec-19-25 08:45AM
Dec-05-25 09:55AM
Dec-04-25 05:00PM
Nov-28-25 07:45AM
Nov-24-25 09:55AM
09:55AM
Nov-19-25 12:00PM
09:55AM
Nov-18-25 04:15PM
Nov-13-25 05:20PM
04:05PM
Nov-12-25 08:30AM
07:29AM
Nov-11-25 04:15PM
Nov-10-25 04:30PM
Oct-16-25 08:00AM
Oct-14-25 08:30AM
Oct-07-25 07:45AM
Sep-23-25 08:00AM
Aug-28-25 08:00AM
Aug-15-25 04:25PM
03:23AM
Aug-14-25 05:20PM
04:05PM
Aug-12-25 05:50PM
Aug-07-25 06:35PM
Aug-05-25 08:15AM
Jul-24-25 05:00PM
Jun-25-25 04:09AM
Jun-10-25 08:00AM
Jun-04-25 07:45AM
May-14-25 04:45PM
May-09-25 03:40AM
May-08-25 06:20PM
04:05PM
May-07-25 11:16AM
May-05-25 09:57AM
Apr-30-25 05:55PM
04:30PM
Apr-29-25 07:30AM
Apr-17-25 08:00AM
Apr-15-25 07:45AM
Mar-26-25 09:59PM
Mar-25-25 08:00AM
Mar-07-25 02:16AM
Mar-06-25 04:05PM
Mar-05-25 07:23AM
Feb-13-25 05:00PM
Jan-13-25 08:00AM
Jan-08-25 07:30AM
Jan-06-25 08:15AM
Dec-10-24 09:55AM
Dec-06-24 09:31AM
09:15AM
09:04AM
Dec-05-24 04:48PM
Dec-03-24 07:46AM
Dec-02-24 07:30AM
Nov-26-24 07:45AM
Nov-12-24 08:00AM
Nov-08-24 12:03PM
Nov-07-24 04:05PM
Nov-06-24 07:41AM
Nov-04-24 06:55AM
Oct-17-24 04:30PM
Oct-16-24 04:15PM
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm's product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It is also focused on developing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company was founded on June 13, 2008 and is headquartered in Mississauga, Canada.
Ph.D.Dr. Arun Swarup Menawat MBA
PresidentDr. Mathieu Burtnyk Ph.D.
Chief Financial OfficerMr. Rashed Dewan
Chief Commercial OfficerMr. Thomas Tamberrino MBA
Investor RelationsMr. Stephen Kilmer